Halozyme Therapeutics
Stock Forecast, Prediction & Price Target
Halozyme Therapeutics Financial Estimates
Halozyme Therapeutics Revenue Estimates
Halozyme Therapeutics EBITDA Estimates
Halozyme Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $443.31M N/A | $660.11M 48.90% | $829.25M 25.62% | Avg: $1.09B Low: $1.09B High: $1.09B avg. 32.54% | Avg: $1.31B Low: $1.31B High: $1.31B avg. 19.65% | Avg: $1.55B Low: $1.55B High: $1.55B avg. 18.15% | Avg: $1.59B Low: $1.59B High: $1.59B avg. 2.35% |
Net Income
% change YoY
| $402.71M N/A | $202.12M -49.80% | $281.59M 39.31% | Avg: $596.00M Low: $596.00M High: $596.00M avg. 111.65% | Avg: $802.22M Low: $802.22M High: $802.22M avg. 34.60% | Avg: $1.00B Low: $1.00B High: $1.00B avg. 25.66% | Avg: $1.02B Low: $1.02B High: $1.02B avg. 2.12% |
EBITDA
% change YoY
| $275.90M N/A | $310.67M 12.60% | $451.94M 45.47% | Avg: $447.83M Low: $447.83M High: $447.83M avg. -0.90% | Avg: $535.87M Low: $535.87M High: $535.87M avg. 19.65% | Avg: $633.18M Low: $633.18M High: $633.18M avg. 18.15% | Avg: $648.10M Low: $648.10M High: $648.10M avg. 2.35% |
EPS
% change YoY
| $2.86 N/A | $1.48 -48.25% | $2.13 43.91% | Avg: $4.44 Low: $4.44 High: $4.44 avg. 108.50% | Avg: $5.98 Low: $5.98 High: $5.98 avg. 34.60% | Avg: $7.51 Low: $7.51 High: $7.51 avg. 25.66% | Avg: $7.67 Low: $7.67 High: $7.67 avg. 2.12% |
Operating Expenses
% change YoY
| $85.99M N/A | $253.28M 194.52% | $299.31M 18.17% | Avg: $213.78M Low: $213.78M High: $213.78M avg. -28.57% | Avg: $255.80M Low: $255.80M High: $255.80M avg. 19.65% | Avg: $302.26M Low: $302.26M High: $302.26M avg. 18.15% | Avg: $309.38M Low: $309.38M High: $309.38M avg. 2.35% |
FAQ
What is Halozyme Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 43.51% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is 596.00M, average is 596.00M and high is 596.00M.
What is Halozyme Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 18.17% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $1.09B, average is $1.09B and high is $1.09B.
What is Halozyme Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 42.72% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is $4.44, average is $4.44 and high is $4.44.